|
Screening and treatment of subclinical hypothyroidism or hyperthyroidism |
Rugge B, Balshem H, Sehgal R, Relevo R, Gorman P, Helfand M |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Rugge B, Balshem H, Sehgal R, Relevo R, Gorman P, Helfand M. Screening and treatment of subclinical hypothyroidism or hyperthyroidism. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 24. 2011 Authors' conclusions Currently there are no studies that evaluate the benefits and harms of screening for subclinical thyroid dysfunction in the primary care setting. Studies of treatment tend to be small and of short duration, and they have failed to demonstrate improvement in quality of life, blood pressure, and weight. The data concerning lipids is inconsistent, but at best, treatment might cause a modest (about 5-percent) improvement in lipid measurements. The lack of any formal data on the harms of treatment makes it difficult to balance the benefits against the harms of treatment. Further research is needed to determine if screening and/or treating subclinical thyroid dysfunction is beneficial or harmful. Indexing Status Subject indexing assigned by CRD MeSH Hyperthyroidism; Hypothyroidisms Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAP@ahrq.hhs.gov AccessionNumber 32013000180 Date abstract record published 20/03/2013 |
|
|
|